Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$743.17M+530.31%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Andrew Toy
- Sector
- Healthcare
- Industry
- Medical - Healthcare Plans
- Employees
- 724
- Beta
- 2.48
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 3.24
Financials
Revenue
$743.17M+530.3%Net Income
$28.00MEBITDA
$28.57MFree Cash Flow
$24.51MEPS (diluted)
$0.05Shares Outstanding (diluted)
545.45M+1189.4%Operating Expenses
$124.44MCash & Debt
$201.32MReturn of Capital
$7.89MDividend per Share
$0.10Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.92B | $-85.55M | $-0.17 |
| 2024 | $1.37B | $-43.01M | $-0.09 |
| 2023 | $1.26B | $-213.36M | $-0.45 |
| 2022 | $1.10B | $-339.57M | $-0.71 |
| 2021 | $1.47B | $-587.76M | $-1.25 |
| 2020 | $672.89M | $-136.39M | $-0.23 |
| 2019 | $462.27M | $-363.74M | $-0.90 |
| 2018 | $281.02M | $-201.93M | $-4.81 |
Valuation
CLOVhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
160+128.57%Social Signal Score
Mentions (8)
- Newsglobenewswire.com·11d ago·Positive
UPDATE – Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D. WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J.
View source ↗ - Newsglobenewswire.com·11d ago·Neutral
Clover Health Welcomes Former U.S. Senator Robert Torricelli and MedPAC Commissioner Dr. Brian J. Miller M.D. WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J.
View source ↗ - Newsmarketbeat.com·18d ago·Positive
Clover Health Sees PPO Edge, Cohort Gains as Medicare Advantage Pricing Tightens Clover Health Investments NASDAQ: CLOV is positioning its Medicare Advantage business to benefit from industry pricing discipline, member retention and the maturation of member cohorts, Interim Chief Financial Officer Clay Thornton said at Jefferies' Healthcare Services and Technology Conference in Nashville.
View source ↗ - Newsglobenewswire.com·35d ago·Positive
Clover Health to Participate in Upcoming Investor Conferences WILMINGTON, Del., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced its participation in the following investor conferences: Interim Chief Financial Officer, Clay Thornton, will present at the 2026 Jefferies Healthcare Services and Technology Conference on Tuesday, September 15, 2026, at 1:40 p.m.
View source ↗ - Newsseekingalpha.com·41d ago·Positive
Clover Health Is A 'Buy' Because Of Its AI Clover Health Investments, Corp. leverages its AI-powered Clover Assistant to drive lower claims costs and improve member profitability. Baseline and bullish DCF valuations yield fair values of $5.02 and $14.10 per share, respectively, versus the current $4.15 price. Key upside drivers include rapid membership growth, AI-enabled cost savings, and a potential $120M Medicare Advantage bonus tied to a 4.5-star CMS rating.
View source ↗ - Newsseekingalpha.com·52d ago·Positive
Clover Health Investments: Real Turnaround, But Already Priced In Clover Health Investments (CLOV) is rated Hold, with operational execution but a cautious outlook due to valuation and litigation risks. CLOV's Medicare Advantage membership grew 48% YoY, revenue and GAAP net income improved, but profitability per member lags FY2024 levels. FY2026 guidance implies negative H2 results; $120M in quality bonus revenue is at risk pending CMS litigation outcome.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Clover Health Is Proving Its Profit Model Clover Health (CLOV) has delivered strong growth, profitability, and improved guidance, supporting my continued Strong Buy rating. CLOV's Medicare Advantage membership grew 48% YoY, with revenue up 56% and gross profit up 54%, driven by cohort maturation and the Clover Assistant platform. Valuation remains attractive at a 78% discount to sector median EV/sales, with upside potential if per-member profitability and SaaS revenue trends persist.
View source ↗ - Newsmarketbeat.com·55d ago·Positive
Clover Health Eyes 2026 GAAP Profit as AI Platform Fuels Medicare Advantage Growth Clover Health Investments NASDAQ: CLOV is positioning its Medicare Advantage model around earlier identification and treatment of chronic conditions, Interim Chief Financial Officer Clay Thornton said during a Canaccord Genuity conference presentation.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $-0.01 per share
Typical surprise +36.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.05 vs $0.04beat
- Wed, May 6$0.07 vs $0.07beat
- Thu, Feb 26$-0.05 vs $-0.10beat
- Tue, Nov 4$-0.05 vs $0.02miss
- Tue, Aug 5$-0.02 vs $-0.01miss
- Tue, May 6$0.05 vs $-0.07beat
Estimates and results for CLOV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CLOV officers and directors.
- Bought
- —
- Sold
- $8.1m
0 trades
34 trades
- Toy Andrewsold
- Reynoso Jamie L.sold
- Oldakowski Joseph Franksold
- Wai Conradsold
- Soares Karensold
- Reynoso Jamie L.sold
- Oldakowski Joseph Franksold
- Thornton Joseph Claysold
66 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CLOV.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.